Active, Not Recruiting
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting - CA180-330
Updated: 19 January, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - Newly-diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who started their first-line Tyrosine Kinase Inhibitor (TKI) treatment on imatinib, dasatinib or nilotinib in accordance with the timelines below - 18 years or older at time of of CP-CML diagnosis a) Imatinib Cohorts - Patients who started their first-line Imatinib treatment between January 2, 2008 and September 30, 2010.Patients fitting this criterion are defined as retrospective Imatinib patients − Patients who started their first-line Imatinib treatment on or after October 1, 2010 b) Dasatinib Cohort - Patients who started their first-line Dasatinib treatment after the drug was approved in this indication c) Nilotinib Cohort - Patients who started their first-line Nilotinib treatment after the drug was approved in this indication - Patients are also eligible when they have already switched to a subsequent therapy (TKI or other) at the time of enrollment, as long as their first-line and subsequent CML treatment information is available at site for data entry into the study Electronic Case Report Form (eCRF) - Receiving treatment at medical practice (eg. community-based, office-based, hospital-based, academic setting, oncology center) Exclusion Criteria: - Patients who are participating in an interventional trial which may influence the management of their CML disease will be excluded Discontinuation Criteria: - Enrolled patients who join an interventional trial which may influence the management of their CML disease will be excluded at the time of entry into the interventional trial
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information